Minimal residual disease provides treatment focus for next chronic lymphocytic leukemia advances

William G. Wierda

doi:10.1200/JCO.2016.69.1972

Minimal residual disease provides treatment focus for next chronic lymphocytic leukemia advances

William G. Wierda

Leukemia

Research output: Contribution to journal › Editorial › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	3722-3723
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	34
Issue number	31
DOIs	https://doi.org/10.1200/JCO.2016.69.1972
State	Published - Nov 1 2016

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2016.69.1972

Cite this

@article{3b5294ddeca94839a37fc3640d47e1e1,

title = "Minimal residual disease provides treatment focus for next chronic lymphocytic leukemia advances",

author = "Wierda, {William G.}",

note = "Funding Information: Novartis, AbbVie, Genentech, Karyopharm Therapeutics, Pharmacyclics, Acerta Pharma, Gilead Sciences, Janssen Pharmaceuticals, Emergent BioSolutions, Juno Therapeutics, Kite Pharma",

year = "2016",

month = nov,

day = "1",

doi = "10.1200/JCO.2016.69.1972",

language = "English (US)",

volume = "34",

pages = "3722--3723",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "31",

}

TY - JOUR

T1 - Minimal residual disease provides treatment focus for next chronic lymphocytic leukemia advances

AU - Wierda, William G.

N1 - Funding Information: Novartis, AbbVie, Genentech, Karyopharm Therapeutics, Pharmacyclics, Acerta Pharma, Gilead Sciences, Janssen Pharmaceuticals, Emergent BioSolutions, Juno Therapeutics, Kite Pharma

PY - 2016/11/1

Y1 - 2016/11/1

UR - http://www.scopus.com/inward/record.url?scp=84993967423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993967423&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.69.1972

DO - 10.1200/JCO.2016.69.1972

M3 - Editorial

C2 - 27573662

AN - SCOPUS:84993967423

SN - 0732-183X

VL - 34

SP - 3722

EP - 3723

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 31

ER -

Minimal residual disease provides treatment focus for next chronic lymphocytic leukemia advances

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this